{"log_id": 1980180482555050638, "direction": 0, "words_result_num": 29, "words_result": [{"probability": {"variance": 0, "average": 0.999924, "min": 0.999802}, "location": {"width": 98, "top": 243, "height": 27, "left": 204}, "words": "特殊人群"}, {"probability": {"variance": 0.041081, "average": 0.898135, "min": 0.492768}, "location": {"width": 137, "top": 307, "height": 28, "left": 248}, "words": "●肾脏损害"}, {"probability": {"variance": 1e-06, "average": 0.99909, "min": 0.995173}, "location": {"width": 795, "top": 364, "height": 38, "left": 292}, "words": "没有在严重肾脏损害病人中使用本品的经验。有肾脏损伤的患者可能不需要调"}, {"probability": {"variance": 2e-06, "average": 0.999127, "min": 0.995466}, "location": {"width": 695, "top": 413, "height": 34, "left": 206}, "words": "整剂量,因为仅有不到2%的药物(本品和代谢产物)经过肾脏清除"}, {"probability": {"variance": 0.00455, "average": 0.980823, "min": 0.704207}, "location": {"width": 427, "top": 460, "height": 30, "left": 215}, "words": "(参见【药代动力学】一特殊患者人群)"}, {"probability": {"variance": 0.0079, "average": 0.955296, "min": 0.777532}, "location": {"width": 136, "top": 527, "height": 26, "left": 249}, "words": "●肝脏损害"}, {"probability": {"variance": 1.3e-05, "average": 0.998235, "min": 0.981094}, "location": {"width": 793, "top": 582, "height": 36, "left": 294}, "words": "本品在肝脏内代谢。中度至重度肝损伤的患者,可使药物在体内暴露量分别增"}, {"probability": {"variance": 1.4e-05, "average": 0.99838, "min": 0.97987}, "location": {"width": 873, "top": 629, "height": 36, "left": 207}, "words": "加56%和85%。有肝损伤的患者由于药物体内暴露量会增加,所以应谨慎给药(参见"}, {"probability": {"variance": 0.009616, "average": 0.976965, "min": 0.527835}, "location": {"width": 515, "top": 677, "height": 32, "left": 219}, "words": "【注意事项】和【药代动力学】—特殊患者人群)"}, {"probability": {"variance": 0.000586, "average": 0.990649, "min": 0.899592}, "location": {"width": 837, "top": 720, "height": 36, "left": 254}, "words": "重度肝损害患者( Child-Pugh肝功能分级为C级)服用本品应减量。将重度肝功"}, {"probability": {"variance": 0.00606, "average": 0.985233, "min": 0.500868}, "location": {"width": 885, "top": 765, "height": 38, "left": 208}, "words": "能损害患者的服药剂量从1250mg减少至750mg/天时,预计可将药;曲线下面积"}, {"probability": {"variance": 0.000149, "average": 0.995498, "min": 0.926932}, "location": {"width": 867, "top": 811, "height": 37, "left": 225}, "words": "AUC)调整至正常范围。然而,目前尚无重度肝功能损害患者使用此剂量调整的临床"}, {"probability": {"variance": 0.012174, "average": 0.97753, "min": 0.425854}, "location": {"width": 632, "top": 859, "height": 33, "left": 208}, "words": "数据(参见【注意事项】和【药代动力学】特殊患者人群"}, {"probability": {"variance": 0, "average": 0.894512, "min": 0.894512}, "location": {"width": 105, "top": 837, "height": 57, "left": 846}, "words": "国"}, {"probability": {"variance": 0, "average": 0.999815, "min": 0.999702}, "location": {"width": 45, "top": 909, "height": 27, "left": 212}, "words": "儿童"}, {"probability": {"variance": 1e-06, "average": 0.999375, "min": 0.997449}, "location": {"width": 143, "top": 953, "height": 28, "left": 256}, "words": "参见儿童用药"}, {"probability": {"variance": 0, "average": 0.999715, "min": 0.999502}, "location": {"width": 96, "top": 1001, "height": 26, "left": 210}, "words": "老年患者"}, {"probability": {"variance": 0, "average": 0.99915, "min": 0.997696}, "location": {"width": 191, "top": 1045, "height": 27, "left": 256}, "words": "参见老年患者用药"}, {"probability": {"variance": 0, "average": 0.999709, "min": 0.999232}, "location": {"width": 147, "top": 1130, "height": 31, "left": 219}, "words": "【不良反应】"}, {"probability": {"variance": 4.3e-05, "average": 0.970951, "min": 0.964385}, "location": {"width": 132, "top": 1132, "height": 41, "left": 878}, "words": " GUANGDONG PHA"}, {"probability": {"variance": 2e-06, "average": 0.998157, "min": 0.995783}, "location": {"width": 143, "top": 1197, "height": 27, "left": 210}, "words": "临床试验数据"}, {"probability": {"variance": 6e-06, "average": 0.996947, "min": 0.993641}, "location": {"width": 196, "top": 1158, "height": 65, "left": 826}, "words": "华润广东"}, {"probability": {"variance": 0, "average": 0.9993, "min": 0.998659}, "location": {"width": 146, "top": 1193, "height": 55, "left": 832}, "words": "医药有限"}, {"probability": {"variance": 0.019011, "average": 0.937554, "min": 0.460294}, "location": {"width": 796, "top": 1224, "height": 44, "left": 265}, "words": "由于临床试验是在各种不同条件下开展的,某种药物临床过验中观察到的不食"}, {"probability": {"variance": 0.018353, "average": 0.963757, "min": 0.395439}, "location": {"width": 847, "top": 1267, "height": 34, "left": 210}, "words": "应发生率不能与另一种药物临床试验中的发生率直接进行比较,也能完全映临"}, {"probability": {"variance": 1e-06, "average": 0.999301, "min": 0.997759}, "location": {"width": 235, "top": 1302, "height": 28, "left": 211}, "words": "实践中观察到的发生率"}, {"probability": {"variance": 4e-06, "average": 0.999364, "min": 0.988217}, "location": {"width": 839, "top": 1347, "height": 35, "left": 252}, "words": "本品的安全性信息来自包括单药和联合其他化疗药物治疗多种肿瘤的研究数据,总"}, {"probability": {"variance": 0.002291, "average": 0.987703, "min": 0.736958}, "location": {"width": 818, "top": 1393, "height": 35, "left": 212}, "words": "计超过15000例患者,其中包括198例拉帕替尼联合卡培他滨治疗的乳腺癌患者"}, {"probability": {"variance": 5.6e-05, "average": 0.995328, "min": 0.96705}, "location": {"width": 866, "top": 1439, "height": 31, "left": 221}, "words": "(EGF100151试验),52例拉帕替尼联合卡培他滨治疗的中国乳腺癌患者(EGF109491"}], "language": 3}